We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Viral Clearance in a Downstream AAV Process

Vaccine Vials
Credit: iStock

Over the last 10 years, adeno-associated virus (AAV) vectors have emerged as primary gene delivery tools, with hundreds in clinical trials and preclinical development. 

As these candidates progress, substantial focus is placed on refining process development and manufacturing for viral vectors, performing inactivation and filtration steps to minimize impurities without compromising product yield. 

This application note shows how chromatographic modes of separation can achieve the necessary levels of virus removal while preserving the integrity of the AAV product.

Download this app note to discover:

  • How to achieve robust viral clearance across various viruses
  • A method that demonstrates high overall process log reduction values
  • An accurate and economic prediction model for AAV purification processes

*Originally published and cited from Bioprocess International 

Brought to you by
Download this App Note for FREE Below
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.